# pancreatic cancer (blogs) — RSS Amplifier Recent posts from the 4 feeds in the RSS Amplifier directory that cover pancreatic cancer. Page: Feed: --- ## [Why CUE-221 Might Not Beat Omalizumab In CSU And Could Still Separate In Food Allergy](https://www.chaotropy.com/why-cue-221-might-not-beat-omalizumab-in-csu-and-could-still-separate-in-food-allergy/) _2026-08-27 · Chaotropy · Chaotropy_ A Phase 2 comparing the "dual-mechanism" anti-IgE with omalizumab in CSU is expected to read out this quarter. Ligelizumab showed how hard beating omalizumab is. Why the IgE levels may indicate whether CUE-221 could still separate in food allergy. ## [Advanced clinical trial for world-first pancreatic cancer breath test begins recruiting in Wales](https://www.pancreaticcancer.org.uk/news-and-blogs/advanced-clinical-trial-for-world-first-pancreatic-cancer-breath-test-begins-recruiting-in-wales/) _2026-08-27 · Harriet Dalwood · Pancreatic Cancer UK_ A world-first breath test for pancreatic cancer is now being trialled on patients outside of England for the first time, at Wrexham Maelor Hospital. The post Advanced clinical trial for world-first pancreatic cancer breath test begins recruiting in Wales appeared first on Pancreatic Cancer UK . ## [FDA Approves RASONQUE™ (daraxonrasib)](https://pancan.org/news/fda-approves-rasonque-daraxonrasib/) _2026-08-26 · Erin Post · Pancreatic Cancer Action Network_ Aug 26, 2026 - By Erin Post The U.S. Food and Drug Administration has granted approval for a new drug targeting the mutations that drive more than 90% of pancreatic cancer cases - a sweeping advance for a disease that has few treatment options and a five-year survival rate of just 13%. RASONQUE™ (daraxonrasib) is approved for the treatment of adults with metastatic pancreatic adenocarcinoma who… ## [Statement from the Pancreatic Cancer Action Network on the U.S. Food And Drug Administration’s Approval of RASONQUE™ (daraxonrasib)](https://pancan.org/press-releases/statement-from-the-pancreatic-cancer-action-network-on-the-u-s-food-and-drug-administrations-approval-of-rasonque-daraxonrasib/) _2026-08-26 · Julie Vasquez · Pancreatic Cancer Action Network_ Aug 26, 2026 - By Julie Vasquez The Pancreatic Cancer Action Network (PanCAN), the leading organization dedicated to advancing progress against pancreatic cancer, released a statement today following U.S. Food and Administration’s (FDA) approval of RASONQUE™ (daraxonrasib) for patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not… ## [Research Spotlight: Highlights from the AACR Drug Discovery and Development Conference](https://pancan.org/news/research-spotlight/research-spotlight-highlights-from-the-aacr-drug-discovery-and-development-conference/) _2026-08-26 · Anna Berkenblit, MD, MMSc · Pancreatic Cancer Action Network_ Aug 26, 2026 - By Anna Berkenblit, MD, MMSc Editor’s note: The “Research Spotlight” series is written by Dr. Anna Berkenblit , PanCAN’s Chief Scientific and Medical Officer. Each month, Dr. Berkenblit shares her insights into the latest news and research in pancreatic cancer. Follow Dr. Berkenblit on X and LinkedIn . I recently had the pleasure of attending the inaugural American Association for… ## [AI, social media and misinformation](https://www.pancreaticcancer.org.uk/news-and-blogs/ai-social-media-and-misinformation/) _2026-08-20 · Callum Dallimore · Pancreatic Cancer UK_ AI, social media and misinformation Keeping safe when searching for health information. The post AI, social media and misinformation appeared first on Pancreatic Cancer UK . ## [Unlocking KRAS: The Power of Advocacy](https://pancan.org/news/unlocking-kras-the-power-of-advocacy/) _2026-08-18 · Julie Vasquez · Pancreatic Cancer Action Network_ Aug 18, 2026 - By Julie Vasquez Every so often, there is a breakthrough in cancer research that changes what people believe is possible. For pancreatic cancer, that moment is now. PanCAN’s Dr. Anna Berkenblit, Cassadie Moravek and Julie Fleshman join a standing ovation after Dr. Brian Wolpin announced the positive results from the RASolute 302 clinical trial of daraxonrasib at the 2026 American… ## [Unlocking KRAS: Turning Science into Survival](https://pancan.org/news/unlocking-kras-turning-science-into-survival/) _2026-08-17 · Erin Post · Pancreatic Cancer Action Network_ Aug 17, 2026 - By Erin Post For decades, pancreatic cancer research was defined by what seemed to be impossible. Researchers couldn’t target the mutations in the RAS family of proteins that drive more than 90% of cases. Often described as a “smooth ball,” the RAS protein is frustratingly free of any pockets or divots that would allow a drug to bind to it. Researchers deemed it “undruggable.” Not… ## [Celebrating Lynne](https://www.pancreaticcancer.org.uk/news-and-blogs/celebrating-lynne/) _2026-08-14 · Callum Dallimore · Pancreatic Cancer UK_ We pay tribute to our dear friend, former trustee and Chair, Lynne Walker, who has sadly died. The post Celebrating Lynne appeared first on Pancreatic Cancer UK . ## [7 New Pancreatic Cancer Clinical Trials — August 2026](https://pancreaticcancerbriefing.substack.com/p/7-new-pancreatic-cancer-clinical) _2026-08-13 · Sagely Health · Pancreatic Cancer Briefing_ KRAS-targeted immune treatments move earlier in care, while surgery gets a light-activated treatment strategy ## [Realtime AI Arbitrage Terminal (Sponsored)](https://crawlproof.com/a/bMan8dDRERk7) _2026-08-13 · **Sponsored**_ Realtime auto-trading across exchanges with scored setups, backtesting, and risk controls. ## [Carrying Forward a Legacy of Service, Hope and Research](https://pancan.org/news/carrying-forward-a-legacy-of-service-hope-and-research/) _2026-08-12 · Carly Eskin · Pancreatic Cancer Action Network_ Aug 12, 2026 - By Carly Eskin When Jane Talbot talks about pancreatic cancer , she doesn’t just speak as a volunteer or advocate . She speaks as a wife, a mother, a grandmother and someone who will do anything to end this disease. Her husband, Frank, was diagnosed with pancreatic cancer in 2008. Like so many families, they knew very little about the disease before his diagnosis. What they did know… ## [In Conversation: Joanne Zborowski, Advocacy Chair, Chicago Affiliate](https://pancan.org/news/in-conversation-joanne-zborowski-advocacy-chair-chicago-affiliate/) _2026-08-12 · Paula Mukherjee · Pancreatic Cancer Action Network_ Aug 12, 2026 - By Paula Mukherjee Editor’s note: Chicago Advocacy Chair Joanne Zborowski spoke with PanCAN’s Paula Mukherjee about her personal connection to PanCAN’s mission and advice for others who have lost a loved one to pancreatic cancer. Paula: What is your connection to PanCAN’s mission? Joanne and Bill. Joanne: My husband, Bill, was diagnosed with Stage 2B pancreatic cancer in 2019. Both… ## [New treatment option for pancreatic cancer in England](https://www.pancreaticcancer.org.uk/news-and-blogs/new-treatment-option-for-pancreatic-cancer-in-england/) _2026-08-12 · Callum Dallimore · Pancreatic Cancer UK_ We are delighted that NHS England has announced that a new treatment combination will be available as a treatment for people with locally advanced pancreatic cancer. The post New treatment option for pancreatic cancer in England appeared first on Pancreatic Cancer UK . ## [Protect the Integrity of Federal Cancer Research](https://pancan.org/news/protect-the-integrity-of-federal-cancer-research/) _2026-08-10 · Carly Eskin · Pancreatic Cancer Action Network_ Aug 10, 2026 - By Carly Eskin Scientific discovery depends on a research system that is rigorous, transparent and guided by experts. Today, that system is at risk. The administration, through the Office of Management & Budget, has proposed significant changes to how federally funded research projects are reviewed and awarded. While Congress has worked to prioritize and increase funding for… ## [Non-Physical Intelligence Has A Ceiling](https://www.chaotropy.com/non-physical-intelligence-has-a-ceiling/) _2026-08-09 · Chaotropy · Chaotropy_ Reasoning alone cannot predict the chaotic physical world. Without a continuous sensory and motor interface to reality, non-physical AI will not deliver the scientific and technological breakthroughs we expect. ## [Enter our prize draw with a chance to win £5,000](https://www.pancreaticcancer.org.uk/news-and-blogs/enter-our-prize-draw-with-a-chance-to-win-5000/) _2026-08-06 · Callum Dallimore · Pancreatic Cancer UK_ We're pleased to announce that we're running a Cash Prize Draw, launching 31st July 2026 and closing 11th September 2026. The post Enter our prize draw with a chance to win £5,000 appeared first on Pancreatic Cancer UK . ## [A Volunteer Q&A Eight Years in the Making](https://pancan.org/news/a-volunteer-qa-eight-years-in-the-making/) _2026-07-23 · Carly Eskin · Pancreatic Cancer Action Network_ Jul 23, 2026 - By Carly Eskin Editor’s note: Back in 2018, PanCAN volunteer and advocate Monica Mishra shared her story with the community. Eight years later, Monica is still passionate about ending pancreatic cancer, the disease that took the lives of both of her parents. In honor of National Parents’ Day, we caught up with Monica to see what has changed in those eight years and learn about her… ## [Unlocking the potential of immunotherapy to treat pancreatic cancer](https://www.pancreaticcancer.org.uk/news-and-blogs/unlocking-the-potential-of-immunotherapy-to-treat-pancreatic-cancer/) _2026-07-21 · Katherine Free · Pancreatic Cancer UK_ We take a look at how immunotherapy works, and explore the research that is taking place to investigate it’s potential as a new treatment for pancreatic cancer. The post Unlocking the potential of immunotherapy to treat pancreatic cancer appeared first on Pancreatic Cancer UK . ## [Early Results Of Verastem's VS-7375 In Pancreatic Cancer, Or How To Read A Reduction In CA19-9](https://www.chaotropy.com/early-results-of-verastems-vs-7375-in-pancreatic-cancer-or-how-to-read-a-reduction-in-ca19-9/) _2026-07-19 · Chaotropy · Chaotropy_ Verastem reported a greater than 50% reduction of CA19-9 in 13 of 14 pretreated patients with metastatic pancreatic cancer treated with 900 mg of its oral KRAS G12D inhibitor VS-7375. Whether CA19-9 reliably tracks tumor burden and can predict survival is another question. ## [Driving Treatment Breakthroughs in Westminster](https://www.pancreaticcancer.org.uk/news-and-blogs/driving-treatment-breakthroughs-in-westminster/) _2026-07-16 · Ella Smith · Pancreatic Cancer UK_ On 16th June, we hosted a parliamentary reception in Westminster, calling on Government to take urgent action to drive treatment breakthroughs for pancreatic cancer. The post Driving Treatment Breakthroughs in Westminster appeared first on Pancreatic Cancer UK . ## [Daily plans, scheduled by AI (Sponsored)](https://crawlproof.com/a/kzfB9n0NVI6R) _2026-07-16 · **Sponsored**_ AI-made daily plans that schedule tasks and protect focus time. ## [Your Advocacy in Action: The Road to Increased Federal Research Funding](https://pancan.org/news/your-advocacy-in-action-the-road-to-increased-federal-research-funding/) _2026-07-09 · Carly Eskin · Pancreatic Cancer Action Network_ Jul 9, 2026 - By Carly Eskin NEW — Congress is Listening – Keep Raising Your Voice! Pancreatic cancer advocates are making their voices heard – and Congress is listening. Because of advocates like you across the country, pancreatic cancer research funding is gaining attention at a critical time. Every email sent, every call made and every personal story shared with lawmakers helps raise awareness… ## [In Conversation: John Walmsley, PurpleStride Team Captain, Rhode Island Affiliate](https://pancan.org/news/in-conversation-john-walmsley-purplestride-team-captain-rhode-island-affiliate/) _2026-07-08 · Paula Mukherjee · Pancreatic Cancer Action Network_ Jul 8, 2026 - By Paula Mukherjee Editor’s Note: Survivor, volunteer and top PurpleStride fundraiser John Walmsley spoke with PanCAN’s Paula Mukherjee about his commitment to providing support to other survivors and passion for fundraising. Paula: What is your connection to PanCAN’s mission? John: It all started in the winter of 2015. I wasn’t feeling like myself. I had no energy. I knew something… ## [16 New Pancreatic Cancer Clinical Trials — July 2026](https://pancreaticcancerbriefing.substack.com/p/16-new-pancreatic-cancer-clinical) _2026-07-07 · Sagely Health · Pancreatic Cancer Briefing_ Precision targeting (KRAS and beyond), novel cell therapies, advanced imaging, and emerging strategies across pancreatic cancer ## [Pancreatic Cancer Action Network Receives $500,000 Gift to Expand Patient Services, Helping Patients Navigate the Right Track: Finding the Right Team, the Right Tests and the Right Treatment](https://pancan.org/press-releases/pancreatic-cancer-action-network-angell-foundation-gift/) _2026-07-07 · Julie Vasquez · Pancreatic Cancer Action Network_ Jul 7, 2026 - By Julie Vasquez The Gift is Part of PanCAN’s $250 Million All Together We Can Campaign to Accelerate Breakthrough Research, Expand Patient Support, and Champion a Thriving Community LOS ANGELES, CALIF. – (July 7, 2026) – The Pancreatic Cancer Action Network (PanCAN) today announced a $500,000 gift from the Paul M. Angell Family Foundation to expand its one-of-a-kind PanCAN Patient… ## [Palantir Is Building The "Brain of The Firm" Envisioned Half a Century Ago](https://www.chaotropy.com/palantir-is-building-the-brain-of-the-firm-envisioned-half-a-century-ago/) _2026-07-05 · Chaotropy · Chaotropy_ An organization can sense and act on its own, but it has always had to borrow its reasoning from the humans it employs. Palantir's ontology hands it a living model of itself, AI supplies the capacity to reason over it, and together they might give the enterprise a functional intelligence of its own. ## [Innovation: America's Perpetual Frontier](https://www.chaotropy.com/americas-perpetual-frontier/) _2026-07-04 · Chaotropy · Chaotropy_ At her 250th birthday, America is still opening frontiers. Boosters settle into the arms of launch towers, machines think at scale, and drugs reach targets once thought undruggable. The rational position is an almost delusional optimism about what Americans build next. ## [Insights from people newly diagnosed](https://www.pancreaticcancer.org.uk/news-and-blogs/insights-from-people-newly-diagnosed/) _2026-07-03 · Emma Banham · Pancreatic Cancer UK_ We welcome the commitment in the National Cancer Plan to establish direct referral pathways over the coming years, ensuring that people newly diagnosed with cancer are routinely connected to trusted charities. The post Insights from people newly diagnosed appeared first on Pancreatic Cancer UK . ## [The Pancreatic Cancer Action Network Announces Leadership Updates to its Board of Directors and Scientific Medical Advisory Board for FY2027](https://pancan.org/press-releases/the-pancreatic-cancer-action-network-announces-leadership-updates-to-its-board-of-directors-and-scientific-and-medical-advisory-board-for-fy2027/) _2026-07-01 · Charaighn Sesock · Pancreatic Cancer Action Network_ Jul 1, 2026 - By Charaighn Sesock LOS ANGELES, CALIF. – (July 1, 2026) – The Pancreatic Cancer Action Network (PanCAN), the leading nonprofit organization dedicated to fighting pancreatic cancer, proudly announces new appointments to its Fiscal Year 2027 Board of Directors and Scientific and Medical Advisory Board (SMAB), effective July 1, 2026. Peter Bernstein of Alexander Wolf & Son will be… ## [23 New Pancreatic Cancer Clinical Trials — June 2026](https://pancreaticcancerbriefing.substack.com/p/23-new-pancreatic-cancer-clinical) _2026-06-15 · Sagely Health · Pancreatic Cancer Briefing_ KRAS drugs, targeted delivery, immune-cell therapies, and new options for pancreatic cancer after surgery, before surgery, and after standard treatments. ## [Nektar's Rezpegaldesleukin: Aiming To Restore Peripheral Immune Balance](https://www.chaotropy.com/nektars-rezpegaldesleukin-aiming-to-restore-peripheral-immune-balance/) _2026-06-14 · Chaotropy · Chaotropy_ Rezpegaldesleukin selectively expands regulatory T cells to restore peripheral immune balance. Phase 2b trials showed impressive, deepening efficacy in atopic dermatitis and meaningful hair regrowth in alopecia areata. ## [Every Channel. One Login. (Sponsored)](https://crawlproof.com/a/XTOwdrYRIhuI) _2026-06-14 · **Sponsored**_ 17,000+ live channels, movies and sports on any device. Free trial, no IP lock. ## [Just 12% of pancreatic cancer patients given the chance to join a clinical trial](https://www.pancreaticcancer.org.uk/news-and-blogs/just-12-of-pancreatic-cancer-patients-given-the-chance-to-join-a-clinical-trial/) _2026-06-04 · Harriet Dalwood · Pancreatic Cancer UK_ Only 12% of people with pancreatic cancer are given the chance to take part in a clinical trial, emphasising the lack of progress in developing treatments. The post Just 12% of pancreatic cancer patients given the chance to join a clinical trial appeared first on Pancreatic Cancer UK . ## [We’re demanding treatment breakthroughs. We’re demanding survival.](https://www.pancreaticcancer.org.uk/news-and-blogs/were-demanding-treatment-breakthroughs-were-demanding-survival/) _2026-06-03 · Callum Dallimore · Pancreatic Cancer UK_ Today marks the launch of our Demand Survival Now petition, calling on governments across the UK to fund more research for treatment breakthroughs The post We’re demanding treatment breakthroughs. We’re demanding survival. appeared first on Pancreatic Cancer UK . ## [Our response to the daraxonrasib clinical study and KRAS inhibitors](https://www.pancreaticcancer.org.uk/news-and-blogs/our-response-to-the-daraxonrasib-clinical-study-and-kras-inhibitors/) _2026-05-31 · Harriet Dalwood · Pancreatic Cancer UK_ Our comment on daraxonrasib results and the promising group of therapies known as KRAS inhibitors. The post Our response to the daraxonrasib clinical study and KRAS inhibitors appeared first on Pancreatic Cancer UK . ## [8 New Clinical Trials (May 2026)](https://pancreaticcancerbriefing.substack.com/p/8-new-clinical-trials-may-2026) _2026-05-28 · Sagely Health · Pancreatic Cancer Briefing_ Our first issue. The month's new pancreatic cancer trials in plain English—organized so you can act and share. ## [Why Licensing A Dual-Mechanism Anti-IgE Antibody Could Be A Major Opportunity For Cue Biopharma](https://www.chaotropy.com/why-licensing-a-dual-mechanism-anti-ige-antibody-could-be-a-major-opportunity-for-cue-biopharma/) _2026-05-17 · Chaotropy · Chaotropy_ Cue Biopharma licensed CUE-221, a dual-mechanism anti-IgE antibody combining picomolar free IgE neutralization with CD23-mediated suppression of new IgE synthesis. Controlled Phase 2 in CSU in mainland China is expected to read out in H2 2026, after which Cue plans a global Phase 2b in food allergy. ## [Mufemilast Phase 2 Data May Partially De-Risk Palisade Bio's PALI-2108](https://www.chaotropy.com/mufemilast-phase-2-data-may-partially-de-risk-palisade-bios-pali-2108/) _2026-05-04 · Chaotropy · Chaotropy_ Hemay’s Phase 2 mufemilast data suggest that oral PDE4 inhibition can drive biologic-range remission rates in moderate-to-severe ulcerative colitis. This class-level evidence may partially de-risk Palisade Bio’s PALI-2108. ## [A Nature Medicine Paper Linking Picloram To Early-Onset Colorectal Cancer Leaves An Open Question](https://www.chaotropy.com/a-nature-medicine-paper-linking-picloram-to-early-onset-colorectal-cancer-leaves-an-open-question/) _2026-04-26 · Chaotropy · Chaotropy_ Maas et al. link picloram to early-onset colorectal cancer in the United States. Yet the incidence of early-onset colorectal cancer rose in parallel in Germany, where publicly available national herbicide sales data report zero picloram sales for 16 consecutive years (1990–2005). ## [Computational Simulation Of Four Non-Covalent KRAS G12D Inhibitors Suggests Verastem's VS-7375 May Achieve The Deepest Signaling Suppression](https://www.chaotropy.com/computational-simulation-of-four-non-covalent-kras-g12d-inhibitors-suggests-verastems-vs-7375-may-achieve-the-deepest-signaling-suppression/) _2026-04-24 · Chaotropy · Chaotropy_ Computational simulation of KRAS G12D conformational cycling across VS-7375, BBO-11818, HRS-4642, and INCB161734 under within-cycle and multi-day dosing suggests VS-7375 may reach 90% suppression at the lowest free drug concentration. ## [Phase 3 Readout Of Daraxonrasib In 2L Metastatic PDAC Marks An Inflection Point For Pancreatic Cancer](https://www.chaotropy.com/phase-3-readout-of-daraxonrasib-in-2l-metastatic-pdac-marks-an-inflection-point-for-pancreatic-cancer/) _2026-04-18 · Chaotropy · Chaotropy_ Median OS 13.2 vs 6.7 months, HR 0.40, in pretreated metastatic pancreatic ductal adenocarcinoma against standard chemotherapy. The era of targeted therapy in pancreatic cancer has finally arrived. ## [Revisiting My PALI-2108 Tissue Penetration Model In Fibrostenotic Crohn's Disease After Phase 1b Readout](https://www.chaotropy.com/revisiting-my-pali-2108-tissue-penetration-model-in-fibrostenotic-crohns-disease-after-phase-1b-readout/) _2026-04-05 · Chaotropy · Chaotropy_ My reaction-diffusion model tried to answer whether the active metabolite of PALI-2108 could penetrate Crohn's strictures but rested on untested assumptions. Phase 1b ileal pharmacokinetics, pharmacodynamics, and endoscopic data from five fibrostenotic Crohn's patients update the priors. ## [Pharmacokinetic Simulation Of Tenax's Oral Levosimendan Suggests Higher Drug Exposure Than IV Dosing In PH-HFpEF](https://www.chaotropy.com/pharmacokinetic-simulation-of-tenaxs-oral-levosimendan-suggests-higher-drug-exposure-than-iv-dosing-in-ph-hfpef/) _2026-03-22 · Chaotropy · Chaotropy_ A computational five-compartment pharmacokinetic model built on published parameters suggests that daily oral levosimendan delivers higher and substantially more stable free drug exposure than the weekly IV infusions behind the significant 6MWD improvement in Phase 2. ## [Johns Hopkins mKRAS Vaccine Trial Strengthens The Case For Elicio's ELI-002](https://www.chaotropy.com/johns-hopkins-mkras-vaccine-trial-strengthens-the-case-for-elicios-eli-002/) _2026-03-09 · Chaotropy · Chaotropy_ A Johns Hopkins Phase 1 trial of a pooled mKRAS vaccine with dual checkpoint blockade strengthens the case that mKRAS peptides generate durable, cross-reactive T cell immunity correlating with disease-free survival in resected pancreatic cancer, consistent with Elicio's AMPLIFY-201 data. ## [Monte Carlo Simulation Of Elicio's Phase II AMPLIFY-7P Study Favors Vaccine Efficacy](https://www.chaotropy.com/monte-carlo-simulation-of-elicios-phase-ii-amplify-7p-study-favors-vaccine-efficacy/) _2026-03-01 · Chaotropy · Chaotropy_ The readout of AMPLIFY-7P for ELI-002 7P in pancreatic cancer was expected by late 2025. Fewer events than projected pushed it to H1 2026. Monte Carlo simulation maps this delay onto control-arm survival and hazard ratio, with efficacy scenarios fitting 2–3× better. ## [Computational Modeling Of Palisade Bio's PALI-2108 Tissue Penetration In Fibrostenotic Crohn's Disease](https://www.chaotropy.com/computational-modeling-of-palisade-bios-pali-2108-tissue-penetration-in-fibrostenotic-crohns-disease/) _2026-02-15 · Chaotropy · Chaotropy_ PALI-2108's Phase 1b data for ulcerative colitis are promising, but UC is mucosal while FSCD is transmural. A computational reaction-diffusion model explores whether PALI-2108 can penetrate Crohn's strictures deeply enough to intercept fibrosis early. ## [Coming soon](https://pancreaticcancerbriefing.substack.com/p/coming-soon) _2025-10-14 · Sagely Health · Pancreatic Cancer Briefing_ This is Pancreatic Cancer Briefing.